Does the kidney injury molecule-1 predict cisplatin-induced kidney injury in early stage?

BackgroundIt is not possible to diagnose acute kidney injury (AKI) in early stages with traditional biomarkers. Kidney injury molecule-1 (KIM-1) is a novel biomarker promising the diagnosis of AKI in early stages. We studied whether urinary and serum KIM-1 (KIM-1U and KIM-1S) concentrations were useful in predicting cisplatin-induced AKI in early stages.MethodsWe prospectively analysed 22 patients on cisplatin treatment. KIM-1S and KIM-1U concentrations were assessed in the samples of the patients on four different time periods (before treatment [BT], first [AT1], third [AT3] and fifth [AT5] day after treatment).ResultsKIM-1U concentrations on the first day after cisplatin treatment in patients with AKI were significantly increased compared to both KIM-1U concentrations of the same patients BT (P = 0.009) and to AT1-KIM-1U concentrations of the patients without AKI (P = 0.008). A receiver operating characteristic analysis revealed that AT1-KIM-1U concentrations may predict AKI with an 87.5% sensitivity an...